Yoon, A. J., Carvajal, R. D., Graboyes, E. M., Kaczmar, J. M., Albergotti, W. G., Kejner, A. E., Troob, S. H., Philipone, E., Anoma, J.-S., Armeson, K. E., Hill, E. G., Richardson, M. S., Woods, T. R., Chera, B. S., Nourollah-Zadeh, F., Lee, B. J., Pandruvada, S., Kourtidis, A., Kingsley, C., … Newman, J. G. (2025). Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1530262

Wu, L. W., & Moy, R. H. (2025). The complex interplay of antibiotic use and immune checkpoint inhibition. The Oncologist, 30(2). https://doi.org/10.1093/oncolo/oyaf010

Lopez, J., Powles, T., Braiteh, F., Siu, L. L., LoRusso, P., Friedman, C. F., Balmanoukian, A. S., Gordon, M., Yachnin, J., Rottey, S., Karydis, I., Fisher, G. A., Schmidt, M., Schuler, M., Sullivan, R. J., Burris, H. A., Galvao, V., Henick, B. S., Dirix, L., … Camidge, D. R. (2025). Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nature Medicine, 31(1), 152–164. https://doi.org/10.1038/s41591-024-03334-7

Stein, M. N., Dumbrava, E. E., Teply, B. A., Gergis, U. S., Guiterrez, M. E., Reshef, R., Subudhi, S. K., Jacquemont, C. F., Senesac, J. H., Bayle, J. H., Scripture, C. D., Chatwal, M. S., Bilen, M. A., Stadler, W. M., & Becerra, C. R. (2024). PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-53220-6

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301

Honig, L. S., Kim, J. M., Gonzalez, W. P., DiMuro, V., Jagannathan, R., Marder, K., Noble, J. M., Bell, K. L., & Mayeux, R. (2024). Clinical Use of Lecanemab at an Academic Medical Center. Alzheimer’s & Dementia, 20(S8). Portico. https://doi.org/10.1002/alz.095181

Diehl, C., Soberón, V., Baygün, S., Chu, Y., Mandelbaum, J., Kraus, L., Engleitner, T., Rudelius, M., Fangazio, M., Daniel, C., Bortoluzzi, S., Helmrath, S., Singroul, P., Gölling, V., Osorio Barrios, F., Seyhan, G., Oßwald, L., Kober-Hasslacher, M., Zeng, T., … Schmidt-Supprian, M. (2024). Hyperreactive B cells instruct their elimination by T cells to curb autoinflammation and lymphomagenesis. Immunity. https://doi.org/10.1016/j.immuni.2024.11.023

Schoenfeld, A. J., Izar, B., Spira, A., Zamarin, D., Spigel, D. R., Hoimes, C., McDermott, D. F., Sehgal, K., Najjar, Y. G., Garon, E. B., Sullivan, R. J., Henick, B., Leal, T. A., Hurwitz, M., McKay, R., Gong, X., Rokade, S., Stager, A. M., Bach, K., … Oft, M. (2024). 1325 T cell and immune activation from a phase 1 study of STK-012, a first-in-class IL-2R α/β selective partial agonist in advanced solid tumors. Regular and Young Investigator Award Abstracts, A1484–A1484. https://doi.org/10.1136/jitc-2024-sitc2024.1325

Daigle, S. R., Elliott, G., Boiko, S., Sommerhalder, D., Noel, M. S., Sharma, S., Balaraman, R., Gutierrez, M., Demel, K., Moy, R. H., Ciccone, D., Zhang, X., Scheuber, A., & Kumar, P. (2024). 83 Tumor immune microenvironment characterization from pre- and post-dose tumors collected from a phase 1/2 study of NDI-101150, a hematopoietic progenitor kinase 1 (HPK1) inhibitor. Regular and Young Investigator Award Abstracts, A91–A91. https://doi.org/10.1136/jitc-2024-sitc2024.0083

Davar, D., Williams, A., Lopez, J., Olson, D., Sato, T., Shaw, H., Friedman, C. F., Thistlethwaite, F., Middleton, M., Lebbe, C., Ma, V. T., Izar, B., Lau, P., Bechter, O., Kirk, P., Yuan, Y., Marshall, S., & Hamid, O. (2024). 694 Phase 1 safety and efficacy of brenetafusp, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). Regular and Young Investigator Award Abstracts, A796–A796. https://doi.org/10.1136/jitc-2024-sitc2024.0694

Iwamoto, F., Rotolo, J. A., Abbate, F., Scuoppo, C., Levrero, C., Buerki, R. a, Dalahmah, O. A., & Haras, A. V. (2024). 991 ST101, an inhibitor of the transcription factor C/EBPß, promotes an immune-active tumor microenvironment in a window of opportunity (WoO) study of patients with glioblastoma (GBM). Regular and Young Investigator Award Abstracts, A1111–A1112. https://doi.org/10.1136/jitc-2024-sitc2024.0991

Li, F., Yang, Z., Savage, T. M., Vincent, R. L., de los Santos-Alexis, K., Ahn, A., Rouanne, M., Mariuzza, D. L., Danino, T., & Arpaia, N. (2024). Programmable bacteria synergize with PD-1 blockade to overcome cancer cell–intrinsic immune resistance mechanisms. Science Immunology, 9(100). https://doi.org/10.1126/sciimmunol.adn9879

Markosyan, N., Kim, I.-K., Arora, C., Quinones-Ware, L., Joshi, N., Cheng, N., Schechter, E. Y., Tobias, J. W., Hochberg, J. E., Corse, E., Liu, K., Rodriguez DiBlasi, V., Chan, L.-C. (Eric), Smyth, E. M., FitzGerald, G. A., Stanger, B. Z., & Vonderheide, R. H. (2024). Pivotal roles for cancer cell–intrinsic mPGES-1 and autocrine EP4 signaling in suppressing antitumor immunity. JCI Insight, 9(21). https://doi.org/10.1172/jci.insight.178644

Hao, L. Y., Lerrer, S., Paiola, M., Moore, E. K., Gartshteyn, Y., Song, R., Goeckeritz, M., Black, M. J., Bukhari, S., Hu, X., & Mor, A. (2024). Exclusion of PD-1 from the immune synapse: A novel strategy to modulate T cell function. Molecular Therapy: Oncology, 32(3), 200839. https://doi.org/10.1016/j.omton.2024.200839

Zhong, J., Lerrer, S., & Mor, A. (2024). An Imaging-Based Assay to Measure the Location of PD-1 at the Immune Synapse for Testing the Binding Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies. BIO-PROTOCOL, 14(1352). https://doi.org/10.21769/bioprotoc.5057

Latzer, P., Zelba, H., Battke, F., Reinhardt, A., Shao, B., Bartsch, O., Rabsteyn, A., Harter, J., Schulze, M., Okech, T., Golf, A., Kyzirakos-Feger, C., Kayser, S., Pieper, N., Feldhahn, M., Wünsche, J., Seitz, C., Hadaschik, D., Garbe, C., … Biskup, S. (2024). A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-51315-8

Nguyen, T. T. T., Gao, Q., Mun, J.-Y., Zhu, Z., Shu, C., Naim, A., Rogava, M., Izar, B., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2024). Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma. Cells, 13(13), 1155. https://doi.org/10.3390/cells13131155

Zaidi, S., Park, J., Chan, J. M., Roudier, M. P., Zhao, J. L., Gopalan, A., Wadosky, K. M., Patel, R. A., Sayar, E., Karthaus, W. R., Kates, D. H., Chaudhary, O., Xu, T., Masilionis, I., Mazutis, L., Chaligné, R., Obradovic, A., Linkov, I., Barlas, A., … Sawyers, C. L. (2024). Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies. Proceedings of the National Academy of Sciences, 121(28). https://doi.org/10.1073/pnas.2322203121

Chen, L. N., Stanifer, B. P., Sonett, J. R., & Shu, C. A. (2024). Advancing neoadjuvant immunotherapy in non-small cell lung cancer (NSCLC): commentary on the Lung Cancer Mutation Consortium 3 trial (LCMC3). AME Clinical Trials Review, 2, 37–37. https://doi.org/10.21037/actr-24-13

Faber, E. B., Baca, Y., Xiu, J., Walker, P., Manji, G., Gholami, S., Saeed, A., Prakash, A., Botta, G. P., Sohal, D., Lenz, H. J., Shields, A. F., Nabhan, C., El-Deiry, W., Seeber, A., Chiu, V., Hwang, J., & Lou, E. (2024). Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status. ESMO Gastrointestinal Oncology, 4, 100042. https://doi.org/10.1016/j.esmogo.2024.100042

Ko, K.-P., Zhang, S., Huang, Y., Kim, B., Zou, G., Jun, S., Zhang, J., Zhao, Y., Martin, C., Dunbar, K. J., Efe, G., Rustgi, A. K., Nakagawa, H., Zhang, H., Liu, Z., & Park, J.-I. (2024). Tumor niche network-defined subtypes predict immunotherapy response of esophageal squamous cell cancer. IScience, 27(5), 109795. https://doi.org/10.1016/j.isci.2024.109795

Atkins, M. B., Jegede, O. A., Haas, N. B., Mcdermott, D. F., Bilen, M. A., Stein, M., Sosman, J., Alter, R., Plimack, E. R., Ornstein, M. C., Hurwitz, M., Peace, D. J., Einstein, D., Catalano, P. J., Hammers, H., & Regan, M. M. (2024). Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A). Journal for ImmunoTherapy of Cancer, 12(4), e008293. https://doi.org/10.1136/jitc-2023-008293

Philips, E. A., Liu, J., Kvalvaag, A., Mørch, A. M., Tocheva, A. S., Ng, C., Liang, H., Ahearn, I. M., Pan, R., Luo, C. C., Leithner, A., Qin, Z., Zhou, Y., Garcia-España, A., Mor, A., Littman, D. R., Dustin, M. L., Wang, J., & Kong, X.-P. (2024). Transmembrane domain–driven PD-1 dimers mediate T cell inhibition. Science Immunology, 9(93). https://doi.org/10.1126/sciimmunol.ade6256

Hu, X., Bukhari, S. M., Tymm, C., Adam, K., Lerrer, S., Henick, B. S., Winchester, R. J., & Mor, A. (2024). Inhibition of IL-25/IL-17RA improves immune-related adverse events of checkpoint inhibitors and reveals antitumor activity. Journal for ImmunoTherapy of Cancer, 12(3), e008482. https://doi.org/10.1136/jitc-2023-008482

Zorko, N. A., Makovec, A., Elliott, A., Kellen, S., Lozada, J. R., Arafa, A. T., Felices, M., Shackelford, M., Barata, P., Zakharia, Y., Narayan, V., Stein, M. N., Zarrabi, K. K., Patniak, A., Bilen, M. A., Radovich, M., Sledge, G., El-Deiry, W. S., Heath, E. I., … Antonarakis, E. S. (2024). Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-024-00797-0

Hilton, J. F., Ott, P. A., Hansen, A. R., Li, Z., Mathew, M., Messina, C. H., Dave, V., Ji, X., Karpinich, N. O., Hirschfeld, S., Ballas, M., & Zandberg, D. P. (2024). INDUCE-2: A Phase I/II, open-label, two-part study of feladilimab in combination with tremelimumab in patients with advanced solid tumors. Cancer Immunology, Immunotherapy, 73(3). https://doi.org/10.1007/s00262-023-03623-z

Straube, J., Bukhari, S., Lerrer, S., Winchester, R. J., Gartshteyn, Y., Henick, B. S., Dragovich, M. A., & Mor, A. (2024). PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-023-03259-5

Ko, B., Tao, K., Brennan, L., Rakhade, S., Chan, C. X., Moone, J.-Y., Zhu, R., Sher, A., Wang, S., Bracero, Y., Fullerton, B., McLellan, B., Geskin, L. J., & Saenger, Y. M. (2024). Evaluating the efficacy of combination and single-agent immunotherapies in real-world patterns of disease progression and survival of metastatic melanoma patients. Melanoma Research, 34(2), 134–141. https://doi.org/10.1097/cmr.0000000000000945

Lin, C.-C., Garralda, E., Schöffski, P., Hong, D. S., Siu, L. L., Martin, M., Maur, M., Hui, R., Soo, R. A., Chiu, J., Zhang, T., Ma, B., Kyi, C., Tan, D. S., Cassier, P. A., Sarantopoulos, J., Weickhardt, A., Carvajal, R. D., Spratlin, J., … De Braud, F. (2023). A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies. OncoImmunology, 13(1). https://doi.org/10.1080/2162402x.2023.2290787

In, G. K., Ribeiro, J. R., Yin, J., Xiu, J., Bustos, M. A., Ito, F., Chow, F., Zada, G., Hwang, L., Salama, A. K. S., Park, S. J., Moser, J. C., Darabi, S., Domingo-Musibay, E., Ascierto, M. L., Margolin, K., Lutzky, J., Gibney, G. T., Atkins, M. B., … VanderWalde, A. M. (2023). Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases. Npj Precision Oncology, 7(1). https://doi.org/10.1038/s41698-023-00471-z

Xu-Monette, Z. Y., Li, Y., Snyder, T., Yu, T., LU, T., Tzankov, A., Visco, C., Bhagat, G., Qian, W., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F., Go, H., Ponzoni, M., Ferreri, A. J. M., Møller, M., … Young, K. H. (2023). Tumor-Infiltrating Normal B Lymphocytes Have Remarkable Prognostic Effects and Are Crucial for Antitumor Immune Responses in Diffuse Large B-Cell Lymphoma. Blood, 142(Supplement 1), 429–429. https://doi.org/10.1182/blood-2023-179972

Hawley, J. E., Obradovic, A. Z., Dallos, M. C., Lim, E. A., Runcie, K., Ager, C. R., McKiernan, J., Anderson, C. B., Decastro, G. J., Weintraub, J., Virk, R., Lowy, I., Hu, J., Chaimowitz, M. G., Guo, X. V., Zhang, Y., Haffner, M. C., Worley, J., Stein, M. N., … Drake, C. G. (2023). Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell, 41(11), 1972-1988.e5. https://doi.org/10.1016/j.ccell.2023.10.006

Daugherty, B. L., Boohaker, R. J., Johnstone, R., Stinson, K., Zhao, G., Zang, M., Qian, J., Wang, T. C., & Lederman, S. (2023). 1345 mTFF2-MSA (mTNX-1700) suppresses tumor growth and increases survival in anti-PD-1 treated CT26.wt subcutaneous and CT26-Luciferase orthotopic syngeneic colorectal cancer models by targeting MDSCs. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.1345

Stein, M. N., Hawley, J., Zibelman, M., Pachynski, R., Dreicer, R., Zarrabi, K. K., Miles, B., Hauke, R. J., Marshall, M. A., Jones, B., Wheeler, V., Sebastian, S., Anderson, K., Vardeu, A., Davis, C., Bendall, J., & Shore, N. (2023). 665 Immunotherapeutic trial in men with biochemical recurrence after definitive local therapy for prostate cancer: A clinical trial in progress. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2023-sitc2023.0665

Parikh, A. S., Li, Y., Mazul, A., Yu, V. X., Thorstad, W., Rich, J., Paniello, R. C., Caruana, S. M., Troob, S. H., Jackson, R. S., Pipkorn, P., Zolkind, P., Qi, Z., Adkins, D., Ding, L., & Puram, S. V. (2023). Immune Cell Deconvolution Reveals Possible Association of γδ T Cells with Poor Survival in Head and Neck Squamous Cell Carcinoma. Cancers, 15(19), 4855. https://doi.org/10.3390/cancers15194855

Kokossis, D., Wei, H. J., Gallitto, M., Yoh, N., McQuillan, N., Tazhibi, M., Berg, X., Zhang, X., Szalontay, L., Gartrell, R., Jovana, P., Zhang, Z., Molotkov, A., Mintz, A., Konofagou, E. E., & Wu, C. C. (2023). Focused Ultrasound for Blood-Brain Barrier Opening and Delivery of Anti-PD1 in Diffuse Midline Gliomas. International Journal of Radiation Oncology*Biology*Physics, 117(2), e523–e524. https://doi.org/10.1016/j.ijrobp.2023.06.1796

Wilky, B., Trent, J. C., Gordon, M., El-Khoueiry, A. B., Bullock, A., Henick, B. S., Schwartz, G. K., Agulnik, M., Mahadevan, D., Patel, J., Grossman, J., Rosenthal, K., O’Day, S. J., & Tsimberidou, A. M. (2023). 1919MO Efficacy and safety of botensilimab (BOT) plus balstilimab (BAL) in patients (pts) with refractory metastatic sarcoma. Annals of Oncology, 34, S1032–S1033. https://doi.org/10.1016/j.annonc.2023.09.1148

Xiang-Xu, W., Jing-Yi, R., Xiao-Wen, W., & Hong-Mei, Z. (2023). 1935P Exploration of tertiary lymphatic structure in soft tissue sarcoma for the prognostic and immunotherapy response. Annals of Oncology, 34, S1039–S1040. https://doi.org/10.1016/j.annonc.2023.09.1164

Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., Luke, J. J., Mitchell, T. C., Mooradian, M. J., Rubin, K. M., Salama, A. K., Shirai, K., Taube, J. M., Tawbi, H. A., Tolley, J. K., … Sullivan, R. J. (2023). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0. Journal for ImmunoTherapy of Cancer, 11(10), e006947. https://doi.org/10.1136/jitc-2023-006947

Ager, C. R., Zhang, M., Chaimowitz, M., Bansal, S., Tagore, S., Obradovic, A., Jugler, C., Rogava, M., Melms, J. C., McCann, P., Spina, C., Drake, C. G., Dallos, M. C., & Izar, B. (2023). KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response. Journal for ImmunoTherapy of Cancer, 11(9), e006782. https://doi.org/10.1136/jitc-2023-006782

Baljevic, M., Moreau, P., Tuchman, S., Callander, N., Lentzsch, S., Van Domelen, D., Bentur, O., Monge, J., & Biran, N. (2023). P-232 Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. Clinical Lymphoma Myeloma and Leukemia, 23, S163. https://doi.org/10.1016/s2152-2650(23)01850-5

Chen, L., Shi, V., Wang, S., Sun, L., Freeman, R., Yang, J., Inkman, M. J., Ghosh, S., Ruiz, F., Jayachandran, K., Huang, Y., Luo, J., Zhang, J., Cosper, P., Luke, C. J., Spina, C. S., Grigsby, P. W., Schwarz, J. K., & Markovina, S. (2023). SCCA1/SERPINB3 suppresses antitumor immunity and blunts therapy-induced T cell responses via STAT-dependent chemokine production. Journal of Clinical Investigation, 133(15). https://doi.org/10.1172/jci163841

Flinn, I. W., Jacobson, C., Nastoupil, L. J., Morschhauser, F., Davies, A. J., Buske, C., Corradini, P., Lopez-Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., & Nahas, M. (2023). P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere, 7(S3), e6350662. https://doi.org/10.1097/01.hs9.0000971324.63506.62

Ho, P., Melms, J. C., Rogava, M., Frangieh, C. J., Poźniak, J., Shah, S. B., Walsh, Z., Kyrysyuk, O., Amin, A. D., Caprio, L., Fullerton, B. T., Soni, R. K., Ager, C. R., Biermann, J., Wang, Y., Khosravi-Maharlooei, M., Zanetti, G., Mu, M., Fatima, H., … Izar, B. (2023). The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity. Cancer Cell, 41(7), 1207-1221.e12. https://doi.org/10.1016/j.ccell.2023.05.014

Chung, R., McKiernan, J., Arpaia, N., Marabelle, A., & Rouanne, M. (2023). Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity. European Journal of Cancer, 187, 58–64. https://doi.org/10.1016/j.ejca.2023.03.037

Park, H.-R., Shiva, A., Cummings, P., Kim, S., Kim, S., Lee, E., Leong, A., Chowdhury, S., Shawber, C., Carvajal, R., Thurston, G., An, J.-Y., Lund, A. W., Yang, H. W., & Kim, M. (2023). Angiopoietin-2–Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma. Cancer Research, 83(12), 1968–1983. https://doi.org/10.1158/0008-5472.can-22-2838

Allen, P. B., Lu, X., Chen, Q., O’Shea, K., Chmiel, J. S., Slonim, L. B., Sukhanova, M., Savas, H., Evens, A. M., Advani, R., Pro, B., Karmali, R., Palmer, B., Bayer, R. A., Eisner, R. M., Mou, E., Dillehay, G., Gordon, L. I., & Winter, J. N. (2023). Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Advances, 7(12), 2670–2676. https://doi.org/10.1182/bloodadvances.2022008116

Bullock, A., Fakih, M., Gordon, M., Tsimberidou, A., El-Khoueiry, A., Wilky, B., Pimentel, A., Margolin, K., Mahadevan, D., Balmanoukian, A., Sanborn, R., Schwartz, G., Abou-Alfa, G., Bockorny, B., Moser, J., Sharma, S., Grossman, J., Rosenthal, K., O’Day, S., … Schlechter, B. (2023). LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC). Annals of Oncology, 34, S178–S179. https://doi.org/10.1016/j.annonc.2023.04.014

Ramirez, A., Jonokuchi, A., Hijiya, N., Gomes, W., Wesley, S., & Kaur, G. (2023). IMMU-19. NIVOLUMAB-INDUCED CNS DEMYELINATION IN A 15-YEAR-OLD WITH CLASSIC HODGKIN LYMPHOMA. Neuro-Oncology, 25(Supplement_1), i53–i53. https://doi.org/10.1093/neuonc/noad073.206

Tshering, L. F., Luo, F., Russ, S., Szenk, M., Rubel, D., Tutuska, K., Rail, J. G., Balázsi, G., Shen, M. M., & Talos, F. (2023). Immune mechanisms shape the clonal landscape during early progression of prostate cancer. Developmental Cell, 58(12), 1071-1086.e8. https://doi.org/10.1016/j.devcel.2023.04.010